The SGLT2 inhibitors dapagliflozin and empagliflozin reduce cardiovascular death or heart failure events, and improve quality of life (QOL) in individuals with heart failure with reduced ejection fraction (HFrEF), with and without type 2 diabetes. Beneficial effects on the kidney have also been demonstrated. More recently, SGLT2 inhibition has been shown to reduce the risk of adverse HF-related outcomes in individuals with HF with mid-range or mildly-reduced EF (HFmrEF) and HF with preserved EF (HFpEF). Benefits in these trials with SGLT2 inhibitors appear early—within one month of initiation of therapy. In addition, the safety of initiating SGLT2 inhibitors in individuals hospitalized with acute HF (de novo or decompensated chronic HF), regardless of ejection fraction, has been shown, with positive outcomes. Furthermore, clinical trial evidence indicates a wide range of eGFRs in which SGLT2 inhibitors can be administered safety and efficaciously. As a result, SGLT2 inhibitors are foundational therapy for patients with HFrEF in HF guidelines, and are recommended in HF guidelines for patients with HFmrEF and HFpEF, patient populations in whom evidence of benefit with pharmacologic therapy had previously been very limited. Therefore, clinicians managing patients with HF need to 1) be aware of the increasing amount of evidence with SGLT2 inhibitors in HF, 2) identify patients for treatment, and 3) incorporate SGLT2 inhibitors in a timely manner in both hospitalized patients and outpatients, and in patients with acute and chronic HF.

Chair
Javed Butler, MD, MPH, MBA

Faculty
Mikhail Kosiborod, MD
Alanna Morris, MD, MSc
Scott Solomon, MD

Introduction
Javed Butler, MD, MPH, MBA (Chair)

SGLT2 Inhibitors for Patients with HFrEF
Mikhail Kosiborod, MD

Clinical Implications/Key Messages from the SGLT2 Inhibitor HFrEF Trails
Javed Butler, MD, MPH, MBA

Exploring the Evidence: SGLT2 Inhibitors for HFmrEF, HFpEF
Scott Solomon, MD

SGLT2 Inhibition Through the Spectrum of Ejection Fraction: Putting it All Together
Alanna Morris, MD, MSc

Using SGLT2 Inhibitors in Practice: Tips for Successful Outcomes (Panel Discussion)
Moderator: Javed Butler, MD, MPH, MBA

Question and Answer/Concluding Remarks

Physicians: In support of improving patient care, the Heart Failure Society of America is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Heart Failure Society of America designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: This educational activity is approved for continuing nursing education (CNE) units by the HFSA, an accredited provider of the American Nurses Credentialing Center. This activity is approved for a maximum of 1.25 contact hours. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists: The Heart Failure Society of America is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education (CPE). This activity is accredited for 1.25 contact hours of knowledge-based CPE under the ACPE universal activity number JA4008267-0000-21-003-L04-P.
Eligibility: Registration for the 2022 HFSA Annual Scientific Meeting and an official name badge are required to attend this symposium.

This activity is supported by an educational grant from AstraZeneca Pharmaceuticals.